【券商聚焦】中泰国际上调信达生物目标价至136港元 指海外授权加速全球化

金吾财讯
Feb 12

(原标题:【券商聚焦】中泰国际上调信达生物(01801)目标价至136港元 指海外授权加速全球化)金吾财讯|中泰国际发布研报指,信达生物(01801.HK)与美国礼来达成第七次合作,获得3.5亿美元首付款及最高85亿美元里程碑付款,同时与日本武田的12亿美元授权协议已生效。公司预计2025年产品销售收入同比增45%至119亿元人民币,其中第四季度增速超60%。核心产品达伯舒收入稳健增长,新上市的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10